Fulcrum Therapeutics Acquires Global Rights to Losmapimod, a Potential Disease-Modifying Therapy for Facioscapulohumeral Muscular Dystrophy Read more
AbbVie Expands Immunology Portfolio in the U.S. with FDA Approval of SKYRIZI (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis Read more
Teva Announces Update on Fremanezumab Clinical Development for use in Episodic Cluster Headache Read more